Clinical Report: Identifying Geographic Atrophy Biomarkers
Overview
This report highlights the importance of optical coherence tomography (OCT) and fundus autofluorescence (FAF) in identifying biomarkers for geographic atrophy (GA). These imaging modalities can detect markers that are not visible during clinical examination, aiding in the assessment of GA progression risk.
Background
Geographic atrophy (GA) is a significant cause of irreversible vision loss associated with age-related macular degeneration (AMD). Early detection and monitoring of GA are critical for timely intervention and management. With new treatments available, understanding the biomarkers that indicate rapid progression of GA is essential for optimizing patient outcomes.
Data Highlights
OCT and FAF imaging can identify reticular pseudodrusen (RPD) and hyperreflective foci, which are associated with increased risk of GA progression. These markers can be detected even in early stages of AMD, providing valuable prognostic information.Key Findings
- OCT and FAF can reveal markers of GA not visible during standard clinical examination.
- Reticular pseudodrusen (RPD) are linked to faster GA progression in patients with early or intermediate AMD.
- Hyperreflective foci on OCT indicate significant risk for GA development.
- GA appears as well-defined regions of hypo-autofluorescence on FAF, indicating RPE atrophy.
- Surrounding RPE health, as indicated by autofluorescence patterns, can predict GA progression rates.
Clinical Implications
Clinicians should utilize OCT and FAF imaging to identify patients at risk for rapid GA progression. Understanding these biomarkers can inform treatment decisions and follow-up intervals, ultimately improving patient management strategies.
Conclusion
The identification of biomarkers through advanced imaging techniques is crucial for the effective management of geographic atrophy. These findings underscore the need for ongoing education and adaptation of clinical practices in light of emerging treatment options.
References
- Jessica Haynes, OD, FAAO, FORS, Dipl ABO, Optometric Management, 2025 -- Identifying Diagnostic and Prognostic Biomarkers of Geographic Atrophy
- Brian Solinsky, MD, et al., Retinal Physician, 2024 -- Insightful Imaging for Geographic Atrophy
- Robyn Guymer, AM, MBBS, PhD, et al., Retinal Physician, 2024 -- Imaging Features That Portend Development of Geographic Atrophy
- Oregon Health & Science University, 2025 -- Age-Related Macular Degeneration Preferred Practice Pattern®
- PubMed, 2025 -- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE
- Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - PubMed
- Considerations for the Identification and Management of Geographic Atrophy: Recommendations from an
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.